Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

XORTX Therapeutics Inc. (XRTX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.9630+0.1228 (+14.62%)
At close: 12:57PM EST
0.9349 -0.03 (-2.92%)
After hours: 04:53PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close0.8402
Open0.9595
Bid0.9200 x 3200
Ask1.0000 x 1800
Day's Range0.9500 - 0.9810
52 Week Range0.6630 - 2.6100
Volume30,443
Avg. Volume48,823
Market Cap14.024M
Beta (5Y Monthly)0.33
PE Ratio (TTM)2.19
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for XRTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • XORTX Therapeutics Inc.
    XRTX: Lowering target price to $3.00XORTX THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $3.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of Low; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

    CALGARY, Alberta, Nov. 25, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, has received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price

  • GlobeNewswire

    XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer

    Dr. Evans brings extensive strategic experience to advance search for XRx-008 Phase 3 development and commercialization partnerCALGARY, Alberta, Nov. 16, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Stacy Evans, M.D., MBA, as Chief Business Officer. The en

  • ACCESSWIRE

    Sidoti's November Micro-Cap Virtual Conference

    Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November 9-10, 2022.

Advertisement
Advertisement